Patients Discontinuing Anti-Obesity Jabs Regain Weight Far More Rapidly Compared to Those on Conventional Diets

Fresh analysis reveals that people who come off new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who halt traditional lifestyle programs.

Published data in a major medical journal points out that while obese people often shed about a fifth of their total mass while using the jabs, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.

"Individuals using these medications need to be informed of the potential of quick rebound weight gain when the medication ends," warns lead investigator Dr. Susan Jebb.

This pace of recovery suggests a return to starting mass within about a year and a half.

Comparing Therapies

The research, which examined 37 of trials involving over 9,000 of patients, compared the results of these new drugs with other pills.

Researchers point out that people who lose weight through diet and exercise typically experience a less rapid weight regain—perhaps 0.1 kg a month—post-intervention.

Explaining the Quick Rebound

Doctors believe the mechanism of the jabs explains the accelerated regain.

GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which controls hunger.

"Sustained high doses of GLP-1 levels far above than the body's typical production may cause the system to produce less of its own natural GLP-1, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a nutrition researcher.

"Discontinuation of this medication leads to appetite is unsuppressed, making binge eating far more likely."

A Chronic Condition?

Health authorities suggest the injections for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.

Many experts say that, given the high risk of relapse, the treatment is often ongoing.

This view is supported by pharmaceutical companies, who say that the results "highlight the long-term character of obesity," similar to managing conditions like hypertension.

Patient Testimonies

Users who have come off the jabs explain a intense resurgence of cravings.

"It felt as if a switch flipping and you're instantly ravenous," said one woman.

This challenge is compounded if patients have not established permanent lifestyle or habit changes during therapy.

Widespread Use

Figures indicate that millions of people in the UK have used these injections in the last 12 months, with demand remaining high.

• Adoption is greater among females than men.
• The 40s and 50s demographic shows the greatest level of interest.
• A large proportion access the drugs through private healthcare rather than public health services.

Ultimately, clinicians caution that while the jabs are effective tools for shedding pounds, they are not a magic cure and lasting health benefits relies on ongoing behavioural support.